Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,007.73
-10.2400-1.01%
Post-market: 1,006.88-0.8550-0.08%17:26 EST
Volume:2.84M
Turnover:2.86B
Market Cap:952.69B
PE:43.91
High:1,020.01
Open:1,015.00
Low:995.07
Close:1,017.97
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.92
T/O Rate:0.30%
Dividend:6.00
Dividend Rate:0.60%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:35.90
PE(LYR):43.91

Loading ...

Eli Lilly Stock (LLY) Rises as Company Reports Progress with Crohn’s Disease Treatment

TIPRANKS
·
Feb 20

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Reuters
·
Feb 20

Eli Lilly initiated with an Overweight at Barclays

TIPRANKS
·
Feb 20

Eli Lilly announces long-term data on Omvoh in Crohn’s disease

TIPRANKS
·
Feb 20

Lilly Says Omvoh Maintains Steroid-Free Remission for Three Years in Crohn’s Disease Patients

Reuters
·
Feb 20

Eli Lilly - Over 90% Maintained Steroid-Free Control Through Three Years

THOMSON REUTERS
·
Feb 20

Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial

TIPRANKS
·
Feb 20

Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating

MT Newswires Live
·
Feb 19

Three multinationals pay almost half of all Irish corporate tax, watchdog says

Reuters
·
Feb 19

U.S. RESEARCH ROUNDUP-EBay, Huntsman, Palo Alto

Reuters
·
Feb 19

Eli Lilly : Berenberg Raises Target Price to $1050 From $950

THOMSON REUTERS
·
Feb 19

Eli Lilly Stock (LLY) in Focus as Zepbound Found to Help Treat Psoriasis

TIPRANKS
·
Feb 18

BRIEF-Lilly's Taltz (Ixekizumab) And Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy In First-Of-Its-Kind Phase 3B Trial

Reuters
·
Feb 18

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Reuters
·
Feb 18

Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy in First-of-Its-Kind Phase 3B Trial for Adults With Psoriasis and Obesity or Overweight

THOMSON REUTERS
·
Feb 18

Eli Lilly: Taltz, Zepbound Met Primary Endpoint of Superiority VS. Taltz Monotherapy in Achieving Complete Skin Clearance, ≥10% Weight Loss

THOMSON REUTERS
·
Feb 18

Eli Lilly: at 36 Weeks, Treatment With Taltz, Zepbound Met Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Feb 18

Eli Lilly: in Secondary Endpoint, Patients Taking Taltz, Zepbound Were 40% More Likely to Achieve Pasi 100 Compared to Those Taking Taltz Alone

THOMSON REUTERS
·
Feb 18

Daiwa Securities Adjusts Price Target on Eli Lilly to $1,250 From $1,230, Maintains Buy Rating

MT Newswires Live
·
Feb 18

BUZZ-Australia's CSL recovers after signing licensing deal with Eli Lilly

Reuters
·
Feb 18